Xilio Therapeutics(XLO) - 2025 Q4 - Annual Results

Financial Estimates - As of December 31, 2025, Xilio Therapeutics, Inc. estimates cash and cash equivalents of approximately $137.5 million[4] - The cash balance estimate is based on preliminary, unaudited information and management estimates for the fiscal year ended December 31, 2025[5] Leadership Changes - The company announced the appointment of Sara M. Bonstein as chair of the Board, succeeding Paul Clancy who retired on January 6, 2026[7]